Molecular network analysis suggests aberrant CREB-mediated gene regulation in the Alzheimer disease hippocampus

Jun-ichi Satoh*a, Hiroko Tabunoki*a and Kunimasa Arima*b
aDepartment of Bioinformatics and Molecular Neuropathology, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan
bDepartment of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8551, Japan

Abstract. The pathogenesis of Alzheimer disease (AD) involves the complex interaction between genetic and environmental factors affecting multiple cellular pathways. Recent advances in systems biology provide a system-level understanding of AD by elucidating the genome-wide molecular interactions. By using KeyMolnet, a bioinformatics tool for analyzing molecular interactions on the curated knowledgebase, we characterized molecular network of 2,883 all stages of AD-related genes (ADGs) and 559 incipient AD-related genes (IADGs) identified by global gene expression profiling of the hippocampal CA1 region of AD brains in terms of significant clinical and pathological correlations (Blalock et al., Proc Natl Acad Sci USA 101: 2173-2178, 2004). By the common upstream search, KeyMolnet identified cAMP-response element-binding protein (CREB) as the principal transcription factor exhibiting the most significant relevance to molecular networks of both ADGs and IADGs. The CREB-regulated transcriptional network included upregulated and downregulated sets of ADGs and IADGs, suggesting an involvement of generalized deregulation of the CREB signaling pathway in the pathophysiology of AD, beginning at the early stage of the disease. To verify the in silico observations in vivo, we conducted immunohistochemical studies of 11 AD and 13 age-matched control brains by using anti-phosphorylated CREB (pCREB) antibody. An abnormal accumulation of pCREB immunoreactivity was identified in granules of granulovacuolar degeneration (GVD) in the hippocampal neurons of AD brains. These observations suggest that aberrant CREB-mediated gene regulation serves as a molecular biomarker of AD-related pathological processes, and support the hypothesis that sequestration of pCREB in GVD granules is in part responsible for deregulation of CREB-mediated gene expression in AD hippocampus.

Keywords: Alzheimer disease, CREB, granulovacuolar degeneration, keymolnet, molecular network, systems biology

1. Introduction

Alzheimer disease (AD) is the most common cause of dementia worldwide, affecting the elderly population, characterized by the hallmark pathology of amyloid-β (Aβ) deposition and neurofibrillary tangle (NFT) formation in the brain. The complex interaction between genetic and environmental factors affecting multiple cellular pathways plays a role in the pathogenesis of AD [1]. The completion of the Human Genome Project in 2003 allows us to systematically characterize the comprehensive disease-associated profiles of the whole human genome. It promotes us to identify disease-specific and stage-specific molecular signatures and biomarkers for diagnosis and prediction of prognosis, and druggable targets for therapy [2]. Actually, global transcriptome analysis of AD brains identified a battery of genes aberrantly regulated in AD, whose role has not been previously
predicted in its pathogenesis. They include reduced expression of kinases/phosphatases, cytoskeletal proteins, synaptic proteins, and neurotransmitter receptors in NFT-bearing CA1 neurons [3], downregulation of neurotrophic factors and upregulation of proapoptotic molecules in the hippocampal CA1 region [4], disturbed sphingolipid metabolism in various brain regions during progression of AD [5], and overexpression of the AMPA receptor GluR2 subunit in synaptosomes of prefrontal cortex [6]. However, in global expression analysis, the important biological implications are often left behind to be characterized, because the huge amount of high-density microarray data is highly complex. Furthermore, cardinal observations obtained from in silico data analysis should be validated by independent wet lab experiments.

Recent advances in systems biology enable us to illustrate a cell-wide map of the complex molecular interactions with aid of the literature-based knowledgebase of molecular pathways [7,8]. In the scale-free molecular network, targeted disruption of several critical components, on which the biologically important molecular connections concentrate, could disturb the whole cellular function by destabilizing the network [9]. Thus, molecular network analysis goes beyond gene-by-gene analysis to shed light on a system-level understanding of molecular relationships among individual genes and networks.

The present study is designed to conduct molecular network analysis of a published microarray dataset of Blalock et al. [10]. It contains genome-wide expression profiling of hippocampal CA1 tissues derived from 22 AD patients with well-defined clinical and pathological stages. They identified 3,413 all stages of AD-related genes (ADGs) and 609 incipient AD-related genes (IADGs), and characterized overrepresented genes by using a bioinformatics tool named Expression Analysis Systematic Explorer (EASE). They found upregulation of tumor suppressors, oligodendrocyte growth factors, and protein kinase A (PKA) modulators, along with downregulation of protein folding/metabolism/transport machinery molecules in incipient AD (IAD) [10]. Recently, a different study followed up analysis of this dataset by weighted gene coexpression network analysis (WGCNA) that calculates a matrix containing all pairwise Pearson correlations between whole microarray probe sets across all subjects in an unsupervised manner. They identified AD-related coexpression modules that play key roles in synaptic transmission, extracellular transport, mitochondrial and metabolic functions, and myelination [11]. However, all of these studies did not clarify the common upstream transcription factors governing molecular networks, closely associated with deregulated gene expression in AD brains. By using KeyMolnet, a bioinformatics tool for analyzing molecular interactions on the curated knowledgebase [12], we characterized the most relevant molecular network of AD brain transcriptome, composed of the genes coordinately regulated by putative common upstream transcription factors.

2. Materials and methods

2.1. The dataset

We performed molecular network analysis of ADGs and IADGs, derived from a dataset of Blalock et al. [10]. It contains gene expression profiling of frozen tissues of the CA1 hippocampus, performed by analyzing with the Affymetrix Human Genome HG-U133A chip that contains 22,215 transcripts. The complete dataset is available from Gene Expression Omnibus (GEO) database (GSE1297). RNA was isolated from the samples of 31 age-matched individuals, composed of nine control subjects, seven patients with incipient AD (IAD), eight with moderate AD, and seven with severe AD [10]. The dataset was normalized following the Microarray Analysis Suite 5.0 (MAS5) algorithm. The clinical stage of AD was defined by the Mini-Mental State Examination (MMSE) score, i.e. control (MMSE > 25), incipient AD (MMSE 20–26), moderate AD (MMSE 14–19), and severe AD (MMSE < 14). The neurofibrillary tangle (NFT) burden was determined in each brain sample, which always showed an inverse relationship with the MMSE score. The statistical correlation between the expression levels of individual genes and the MMSE and NFT scores was evaluated by Pearson’s correlation tests and ANOVA. With respect to overall correlations across 31 subjects, the study identified 3,413 ADGs, composed of 1,977 upregulated and 1,436 downregulated genes in all stages of AD patients versus control subjects. The study also identified 609 IADGs, composed of 431 upregulated and 178 downregulated genes in IAD patients versus control subjects.

2.2. Gene ID conversion

We converted Affymetrix probe IDs into the corresponding National Center for Biotechnology Information (NCBI) Entrez Gene IDs by using the
2.3. Molecular network analysis

KeyMolnet is a comprehensive knowledgebase, originally developed by the Institute of Medicinal Molecular Design (IMMD), Tokyo, Japan [12]. It covers virtually all the relationships heretofore reported among human genes, molecules, diseases, pathways and drugs, whose information is manually collected, carefully curated, and regularly updated by expert biologists. The database is categorized into the core contents collected, or the secondary contents extracted from abstracts of PubMed database and Human Protein Reference database (HPRD). By importing microarray data, such as the list of Entrez Gene ID and fold changes of individual probes, KeyMolnet automatically provides corresponding molecules as a node on networks.

The common upstream search is a mode of network analysis that extracts the most relevant molecular network composed of the genes coordinately regulated by putative common upstream transcription factors. The generated network was compared side by side with 403 human canonical pathways of the KeyMolnet library. To reduce the potential bias toward the selection of major pathways, all well-established biological pathways covering both major and minor classes were collected by extensive search of valid review articles with journal impact factors greater than 10. Further information on the canonical pathways of KeyMolnet is available from IMMD upon request (www.immd.co.jp/en/keymolnet/index.html). The algorithm counting the number of overlapping molecular relations between the extracted network and the canonical pathway makes it possible to identify the canonical pathway showing the most significant contribution to the extracted network. It is constructed by modification of the algorithm developed for GO::TermFinder [14]. The significance in the similarity between the extracted network and the canonical pathway is scored following the formula, where O = the number of overlapping molecular relations between the extracted network and the canonical pathway, V = the number of molecular relations located in the extracted network, C = the number of total molecular relations composed of approximately 110,000 sets, and the X = the sigma variable that defines coincidence.

\[
\text{Score} = -\log_2(\text{Score}(p))
\]

\[
\text{Score}(p) = \sum_{x=O}^{\text{Min}(C,V)} f(x)
\]

\[
f(x) = C \cdot \frac{T - C \cdot C_{V - x}}{T \cdot C_V}
\]

2.4. Immunohistochemistry

The autopsied brain samples were provided by Research Resource Network (RRN), Japan. Written informed consent was obtained form all the cases. The Ethics Committee of National Center of Neurology and Psychiatry approved the present study. The study population consists of 11 AD patients composed of five men and six women with the mean age of 71 ± 9 years, and 13 other neurological disease (termed as non-AD) patients composed of six men and seven women with the mean age of 69 ± 9 years. The non-AD cases include three patients with Parkinson disease (PD), two with multiple system atrophy (MSA), four with amyotrophic lateral sclerosis (ALS), and four with myotonic dystrophy. The average of brain weight was 1,038 ± 163 gram in AD cases and 1,195 ± 182 gram in non-AD cases. Brain tissues of the hippocampus and the motor cortex were fixed with 4% paraformaldehyde (PFA), embedded in paraffin, and processed for ten micron-thick serial sections. All AD cases were satisfied with the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) criteria for diagnosis of definite AD [15]. They were categorized into the stage C of amyloid deposition and the stage VI of neurofibrillary degeneration, following the Braak’s staging [16].

The immunohistochemistry protocol was described elsewhere [17]. In brief, after deparaffinization, tissue sections were heated in 10 mM citrate sodium buffer, pH 6.0 by autoclave at 125°C for 30 sec in a temperature-controlled pressure chamber (Dako, Tokyo, Japan). They were incubated with 3% hydrogen peroxide-containing methanol to block the endogenous peroxidase activity, and with phosphate-buffered saline (PBS) containing 10% normal goat serum (NGS) at room temperature (RT) for 15 min to block non-specific staining. Then, tissue sections were stained at 4°C overnight with rabbit polyclonal anti-phosphorylated cAMP-response element-binding protein (pCREB) an-
tibody at a dilution of 1:1,000 (Y011052; Applied Biological Materials, Richmond, BC, Canada). This antibody was produced against a synthesized phosphopeptide spanning R-P-SP-Y-R, derived from the human CREB1 amino acid sequences surrounding the serine 133 residue (Ser-133), and purified by affinity-chromatography with an epitope-specific phosphopeptide. The specificity of the antibody was verified by western blot analysis of a human neuronal cell line exposed to forskolin in culture (not shown). After several washes, the tissue sections were incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit antibody (Nichirei, Tokyo, Japan), and colorized with DAB substrate (Vector Laboratories, Burlingame, CA, USA), followed by a counterstain with hematoxylin. The adjacent sections were immunolabeled with mouse monoclonal anti-GFAP antibody (Nichirei). For negative controls, the step of incubation with primary antibodies was omitted.

3. Results

3.1. Transcriptome dataset of Alzheimer disease hippocampus

The dataset of Blalock et al. [10] contains genome-wide transcriptome of the hippocampus CA1 region, derived from nine control subjects, seven patients with incipient AD (IAD), eight with moderate AD, and seven with severe AD. They identified 3,413 all stages of AD-related genes (ADGs) and 609 IAD-related genes (IADGs) based on significant clinical and pathological correlations. We performed extensive curation of their data, and extracted 2,883 Entrez Gene IDs of ADGs, composed of 1,675 upregulated and 1,208 downregulated genes in all stages of AD patients versus control subjects (Supplementary Tables 1 and 2 online). We also identified 559 Entrez Gene IDs of IADGs, composed of 395 upregulated and 164 downregulated genes in IAD patients versus control subjects (Supplementary Tables 3 and 4 online).

3.2. The molecular network analysis of ADGs and IADGs identified CREB as a central transcription factor

First, we imported 2,883 Entrez Gene IDs of ADGs, along with the expression levels, into KeyMolnet (the version 4.9.9.616 of July 1, 2009). The common upstream search of the core contents generated a complex network composed of 508 fundamental nodes with 735 molecular relations, arranged with respect to subcellular location of the molecules by the editing function of KeyMolnet (Fig. 1). By statistical evaluation, the extracted network showed the most significant relationship with transcriptional regulation by CREB with the score of 229 and score \((p) = 1.141E-069\), where CREB is located as a common upstream transcription factor that has direct connections with 50 nodes, all of which are known CRE-responsive genes (Fig. 2 and Table 1). Unexpectedly, the CREB-regulated transcriptional network is comprised of not only 17 upregulated ADGs but also 26 downregulated ADGs. These results suggest not simply either overactivation or hypactivation of CREB but an involvement of generalized deregulation of the CREB signaling pathway in the pathophysiology of AD. The second rank pathway was transcriptional regulation by nuclear factor kappa B (NF-\(\kappa\)B) with the score of 158 and score \((p) = 1.945E-048\) (Supplementary Fig. 1 online), while the third rank was transcriptional regulation by vitamin D receptor (VDR) with the score of 140 and score \((p) = 5.841E-042\) (Supplementary Fig. 2 online).

Next, we imported 559 Entrez Gene IDs of IADGs and the expression levels into KeyMolnet. Subsequently, the common upstream search of the core contents generated a less complex network composed of 143 fundamental nodes with 190 molecular relations (Fig. 3). By statistical evaluation, the extracted network showed again the most significant relationship with transcriptional regulation by CREB with the score of 71 and score \((p) = 3.325E-022\), comprised of 5 upregulated and 5 downregulated IADGs (Fig. 4 and Table 1). These results suggest that functional impairment of CREB in the AD hippocampus is beginning at the early stage of the disease. The second rank pathway was transcriptional regulation by NF-\(\kappa\)B or by glucocorticoid receptor (GR) with the identical score of 53 and score \((p) = 1.163E-016\) between both.

3.3. Granulovacuolar degeneration in hippocampal neurons of AD brains expressed pCREB immunoreactivity

It is well known that a wide range of extracellular stimuli activates CREB by inducing phosphorylation of Ser-133 on CREB, thereby it functions as a transcriptional activator [18,19]. Because the molecular network of both ADGs and IADGs reflects persistent impairment of CREB function in the AD hippocampus, we studied the expression of Ser-133-phosphorylated
CREB (pCREB) in 11 AD and 13 age-matched control brains by immunohistochemistry. The granular components of granulovacuolar degeneration (GVD), accumulated in the cytoplasm of hippocampal pyramidal neurons in both AD and non-AD brains, expressed strong immunoreactivity against pCREB (Fig. 5, panels a-d). However, the nuclei of hippocampal pyramidal neurons were devoid of pCREB immunoreac-

### Table 1

The list of 51 genes constructing the CREB-regulated transcriptional network in AD hippocampus

| KeyMolnet symbol | Gene name | Upregulation or downregulation | Involvement in IAD network | Swiss-Prot ID |
|------------------|-----------|--------------------------------|-----------------------------|---------------|
| 14-3-3epsilon    | 14-3-3 protein epsilon | down |                            | P62258        |
| AChE             | acetylcholinesterase    | down |                            | P22303        |
| AbR              | arylhydrocarbon receptor | km  |                            | P35869        |
| BCKDH            | branched-chain-alpha-keto acid dehydrogenase | down |                            | P09622, P11182, P12694, P21953 |
| Bcl-2            | B-cell lymphoma 2       | up   |                            | P10415        |
| BiP              | 78 kDa glucose-regulated protein | down | yes | P11021 |
| BRCA1            | breast cancer type 1 susceptibility protein | up |    | P38398 |
| CREB             | cAMP-response-element-binding-protein | km  | yes | P16220 |
| C/EBPb           | CCAAT/enhancer binding protein beta | km  | yes | P17676 |
| CCK              | cholecystokinin         | down |                            | P06307        |
| CDK5             | cyclin dependent kinase 5 | down |                            | Q00535        |
| Chromogranin A   | chromogranin A          | down |                            | P10645        |
| CPT              | carnitine palmitoyl transferase | up  | yes | P04146, Q92523, Q8TCG5, P23786 |
| CREB             | cAMP-response-element-binding-protein | km  | yes | P16220 |
| CRF              | corticotropin-releasing factor | down | yes | P06850        |
| cyclinA          | cyclin A                | down |                            | P78396, P20248 |
| cyto-c           | cytochrome c            | down |                            | P99999        |
| DIO2             | type II iodothyronine deiodinase | down |                            | Q29813        |
| Egr1             | early growth response protein 1 | up |    | P18146 |
| ENO2             | neuron-specific enolase | down |                            | P90104        |
| FNI              | fibronectin 1           | down |                            | P02751        |
| GADD34           | protein phosphatase 1, regulatory subunit 15A | up |    | O75807 |
| GluR1            | glutamate receptor 1    | down |                            | P42261        |
| GR               | glucocorticoid receptor | km  | yes | P04150        |
| GS               | glutamine synthetase    | down | yes | P15104        |
| HO-1             | heme oxygenase 1        | up   |                            | P09601        |
| ICAM-1           | intercellular adhesion molecule 1 | up  |    | P05362    |
| IGF1             | insulin-like growth factor 1 | down |    | P013343, P05019 |
| IL-6             | interleukin-6           | up   |                            | P05231        |
| JunD             | transcription factor Jun-D | up  | yes | P17535        |
| LDH              | L-lactate dehydrogenase | down |                            | Q6ZM83, Q9BYZ2, P00338, P07195, P07864 |
| MIF              | microphthalmia-associated transcription factor | up  | yes | O75030        |
| MnSOD            | manganese superoxide dismutase | up  |    | P04179        |
| NF-L             | neurofilament triplet L protein | down |    | P07196        |
| NPY              | neuropeptide Y          | down |                            | P01303        |
| NR4A2            | orphan nuclear receptor NR4A2 | km  |    | P43354        |
| ODC              | ornithine decarboxylase | up   |                            | P11926        |
| PC                | prohormone convertase   | down |                            | P29120, P16519, Q16549 |
| PCB              | pyruvate carboxylase    | up   | yes | P11498        |
| PCNA             | proliferating cell nuclear antigen | down |    | P12004        |
| PER1             | period circadian protein 1 | up  | yes | Q15534        |
| PER2             | period circadian protein 2 | up  |    | Q15555        |
| Pit-1            | pituitary-specific positive transcription factor 1 | km  | yes | P28069        |
| PPT-A            | preprochymotrypsin A   | down | yes | P20366        |
| proenkephalin    | proenkephalin          | down |                            | P01213, P01210 |
| SGK              | serum- and glucocorticoid-inducible kinase | up  | yes | Q00141, Q9HBY8, Q96BR1 |
| SST              | somatostatin           | down |                            | P61278        |
| STAT3            | signal transducer and activator of transcription 3 | km  | yes | P40763        |
| SynapsinI        | synapsin-1             | down |                            | P17600        |
| TGFb2            | transforming growth factor beta 2 | up  |    | P61812        |
| TyrAT            | tyrosine aminotransferase | up  |    | P17735        |
| VIP              | vasoactive intestinal peptide | down |    | P01282        |

Km represents additional nodes unlisted in the original set of 2,883 ADGs but automatically incorporated from KeyMolnet core contents following the network-searching algorithm.
Fig. 1. Molecular network of all stages of AD-related genes (ADGs). The list of 2,883 Entrez Gene IDs corresponding to ADGs was imported into KeyMolnet. The common upstream search of the core contents generated a network composed of 508 fundamental nodes with 735 molecular relations, arranged with respect to subcellular location of the molecules. Red nodes represent upregulated genes, whereas blue nodes represent downregulated genes. White nodes exhibit additional nodes extracted automatically from the core contents incorporated in the network to establish molecular connections. The direction of molecular relation is indicated by red-colored dash line with arrow (transcriptional activation) or blue-colored dash line with arrow and stop (transcriptional repression).

4. Discussion

Since microarray analysis usually produces a large amount of gene expression data at one time, it is often difficult to find out the meaningful relationship be-
The CREB-regulated transcriptional network of ADGs. The CREB-regulated transcriptional network extracted from the ADG network of Fig. 1 consists of a central node of CREB and 50 connecting nodes of CREB target genes listed in Table 1.

CREB is the prototype stimulus-inducible transcription factor binding as a dimer to a conserved cAMP-responsive element (CRE) of the target genes [18,19]. CREB is promptly activated in response to a wide range of extracellular stimuli, such as growth factors, peptide hormones, and neuronal activity, all of which activate various protein kinases such as PKA, mitogen-activated protein kinases (MAPKs), and Ca²⁺/calmodulin-dependent protein kinases (CAMKs). They phosphorylate Ser-133 located in the KID domain of CREB. The phosphorylation of Ser-133 on CREB (pCREB) induces the recruitment of a transcriptional coactivator named CREB binding protein (CBP), thereby activates the expression of CRE-responsive genes. The CREB target genes play key roles in neuronal development and are associated with biological implications from such a large quantity of available data. To overcome this difficulty, we have made a breakthrough to identify the molecular network most closely associated with microarray data by using a novel bioinformatics tool named KeyMolnet [12]. KeyMolnet includes the highly reliable information on a wide range of human proteins, small molecules, molecular relations, diseases, and drugs. All the contents are manually collected and carefully curated by experts from the literature and public databases. The application of KeyMolnet has an advantage that the user can easily merge microarray data with the comprehensive knowledgebase to characterize pathophysiology-meaningful networks from the high-throughput gene expression data [20,21]. In particular, the common upstream search is the most powerful approach to identify a battery of common transcription factors governing molecular networks closely associated with aberrant gene expression. By using KeyMolnet, we characterized the molecular network of 2,883 ADGs and 559 IADGs that show significant correlations with MMSE score and NFT burden in either all stages of AD or the early stage of AD [10]. We identified CREB as the central transcription factor that exhibits the most significant relevance to molecular networks of both ADGs and IADGs.
opment, synaptic plasticity, and neuroprotection in the central nervous system (CNS). Currently, we are able to search thousands of CREB target genes via the web-accessible database (natural.salk.edu/CREB) [22]. In the present study, the CREB-regulated transcriptional network consisted of both upregulated and downregulated sets of ADGs and IADGs. These observations suggest not simply either overactivation or hypoactivation of CREB but an involvement of generalized deregulation of the CREB signaling pathway in the pathophysiology of AD, emerging at the early stage of the disease.

To verify the in silico observations in vivo, we conducted immunohistochemical observations of 11 AD and 13 age-matched non-AD control brains by using anti-pCREB antibody. We identified aberrant pCREB immunoreactivity concentrated in granules of GVD in the hippocampus of both AD and non-AD brains, where the number of pCREB-immunoreactive GVD-bearing neurons was significantly greater in AD than non-AD cases. These results suggest that pCREB-immunoreactive GVD does not itself serve as an AD-specific diagnostic marker. However, these observations would support the hypothesis that sequestration of pCREB in GVD granules might be in part attributable to disturbed CREB-regulated gene expression in AD hippocampus.

Physiologically, CREB plays a pivotal role in the long-term memory formation in CA1 hippocampal neurons [23]. A previous study by western blot analysis showed that pCREB levels are reduced in AD brain tissues, although the cellular and subcellular location of pCREB was not characterized [24]. In a rat model, cortical impact injury induces a cognitive impairment, associated with reduced expression of CREB and target genes in the ipsilateral hippocampus [25]. A phosphodiesterase-4 inhibitor rolipram, by activating the cAMP/PKA/CREB signaling pathway, ameliorates deficits in long-term potential and cognitive function.

Fig. 3. Molecular network of incipient AD-related genes (IADGs). The list of 559 Entrez Gene IDs corresponding to IADGs was imported into KeyMolnet. The common upstream search of the core contents generated a network composed of 143 fundamental nodes with 190 molecular relations, arranged with respect to subcellular location of the molecules. Red nodes represent upregulated genes, whereas blue nodes represent downregulated genes. White nodes exhibit additional nodes extracted automatically from the core contents incorporated in the network to establish molecular connections. The direction of molecular relation is indicated by red-colored dash line with arrow (transcriptional activation) or blue-colored dash line with arrow and stop (transcriptional repression).
in a transgenic mouse model of AD [26]. Overactivation of calpain induces proteolysis of PKA subunits, resulting in inactivation of CREB in AD brains [27]. High levels of intracellular Aβ induce sustained hyperphosphorylation of CREB that blocks nuclear translocation of pCREB, resulting in inactivation of CREB-regulated gene expression [28]. The Aβ oligomers inactivate MAPKs, PKA, and cyclic GMP-dependent protein kinase essential for CREB activation in hippocampal neurons [29–31]. Long-term treatment with green tea catechin reduces the levels of Aβ oligomers, thereby restores the expression of CREB target genes, such as BDNF and PSD95, in the hippocampus [32]. All of these observations support a possible scenario that a defect in the CREB-mediated signaling pathway in hippocampal neurons causes cognitive disturbance during progression of AD. Therefore, CREB serves as a promising molecular target for treatment of dementia in AD [33].

The accumulation of misfolded cellular proteins within neurons, due to a defect in the clearance system, such as the ubiquitin-proteasome system (UPS) and the autophagic-lysosomal system, is a pathological hallmark of various neurodegenerative diseases [34]. Degradation of CREB involves nuclear export of CREB, modification by polyubiquitination, and processing for proteasomes, suggesting that UPS is a major system for CREB degradation under normal physiological conditions [35,36]. We identified an abnormal accumulation of pCREB in GVD granules of hippocampal neurons in AD brains. GVD is a pathological change characterized by electron-dense granules within double membrane-bound cytoplasmic vacuoles that highly resemble autophagosomes [37]. The emergence of GVD is confined to hippocampal pyramidal neurons of AD brains, and infrequently found in those of other neurodegenerative diseases. GVD is barely detectable in other brain regions. It plays a role in sequestration and degradation of unnecessary proteins and organelles in neurons exposed to aging-related stressful insults [37]. The active forms of caspase-3, glycogen synthase kinase-3β (GSK-3β), c-Jun N-terminal kinase
Fig. 5. pCREB immunoreactivity in AD and non-AD brains. The tissue sections of the hippocampus (HC) and the motor cortex (MC) of 11 AD patients and 13 other neurological disease (non-AD) patients were immunolabeled with an antibody against Ser-133-phosphorylated CREB (pCREB). (a) HC CA1 of a 59-year-old AD patient. The granular components of granulovacuolar degeneration (GVD) accumulated in the cytoplasm of pyramidal neurons exhibit strong pCREB immunoreactivity. (b) HC CA1 of a 68-year-old AD patient. The granular components of GVD accumulated in the cytoplasm of pyramidal neurons exhibit strong pCREB immunoreactivity. (c) HC CA3 of a 77 year-old AD patient. The vacuolar components of GVD are devoid of pCREB immunoreactivity. Neuritic processes of hippocampal neurons express variable levels of pCREB immunoreactivity. (d) HC CA1 of a 68 year-old myotonic dystrophy patient. The granular components of GVD accumulated in the cytoplasm of pyramidal neurons exhibit strong pCREB immunoreactivity. (e) MC of a 72-year-old AD patient. Substantial numbers of neuronal axons in the white matter of the motor cortex express strong pCREB immunoreactivity. (f) The periventricular white matter in the hippocampus of an 80 year-old AD patient. A subpopulation of reactive astrocytes express strong pCREB immunoreactivity located predominantly in their nuclei.

(JNK), c-Jun, pancreatic eIF2-alpha kinase (PERK), and TAR DNA-binding protein-43 (TDP-43), all of which are modified by phosphorylation, are found to be accumulated in GVD granules of hippocampal neurons in AD brains [38–43]. GVD granules also include cytoskeletal proteins, such as neurofilament, tubulin, and tau, along with ubiquitin [44,45]. At present, the precise implication of pCREB accumulation in GVD granules of hippocampal neurons in AD brains remains unknown. Importantly, degenerating neurons but not apparently healthy neurons in AD brains exhibit the profuse accumulation of autophagic vacuoles (AVs), owing to decreased clearance of AVs [46], suggesting an involvement of impaired autophagy function in formation of pCREB-accumulated GVD granules.

We found that neuronal axons, neuritic processes, and a subpopulation of reactive astrocytes also express pCREB immunoreactivity in both AD and non-AD brains. In a rat model of neuronal injury, reactive astrocytes express pCREB following intracerebroventricular injection of kinate [47]. In developing mouse DRG neurons, CREB protein is translated in response to NGF from the corresponding mRNA located in axons, and subsequently translocated to the cell body via a retro-
Fig. 6. The number of pCREB-immunoreactive GVD-bearing neurons in the hippocampus of AD and non-AD brains. The number of pCREB-immunoreactive GVD-bearing neurons was counted in the CA1, CA2, CA3 and CA4 sectors and the subiculum of the hippocampus, derived from 11 AD cases and 13 age and sex-matched other neurological disease (non-AD) cases. Non-AD cases include three patients with Parkinson disease (PD), two with multiple system atrophy (MSA), four with amyotrophic lateral sclerosis (ALS), and four with myotonic dystrophy. The total number in each case is plotted. The statistical difference in the numbers between AD and non-AD was evaluated by Mann-Whitney’s U test.

grade axonal transport [48]. These observations would provide an explanation for glial or axonal location of CREB and pCREB.

We identified NF-κB-regulated gene expression as the second significant pathway in the molecular network of AGDs and IADGs (Supplementary Fig. 1 online). The NF-κB family, consisting of NF-κB1 (p50/p105), NF-κB2 (p52/p100), RelA (p65), RelB, and c-Rel, acts as a central regulator of innate and adaptive immune responses, cell proliferation, and apoptosis [49]. Under unstimulated conditions, NF-κB is sequestered in the cytoplasm via non-covalent interaction with the inhibitor of NF-κB (IκB). Proinflammatory cytokines and stress-inducing agents activate specific IκB kinases that phosphorylate IκB proteins. Phosphorylated IκB is ubiquitinated, and then processed for proteasome-mediated degradation, resulting in nuclear translocation of NF-κB that regulates the expression of hundreds of target genes by binding to the consensus sequence located in the promoter. Importantly, the expression of NF-κB p65 is enhanced in neurons, NFTs, and dystrophic neurites in the hippocampus and entorhinal cortex of AD brains [50]. A NF-κB-inducible microRNA, MiR-146a, reduces the expression of complement factor H (CFH), a negative regulator of proinflammatory responses in AD brains [51].

We also identified gene expression regulated by vitamin D receptor (VDR) as the third significant pathway in the molecular network of AGDs (Supplementary Fig. 2 online). Vitamin D plays a neuroprotective role by modulating neuronal calcium homeostasis. By forming a heterodimer with the retinoid X receptor (RXR), VDR activates the transcription of target genes with the vitamin D response element (VDRE) in the promoter. A significant association is found between VDR gene polymorphism and development of AD [52]. In AD brains, the expression of VDR and its target calbindin D28K is downregulated in hippocampal CA1 neurons [53].

In conclusion, KeyMolnet has effectively characterized molecular network of 2,883 ADGs and 559 IADGs. The common upstream search identified CREB as the principal transcription factor that regulates molecular networks of both ADGs and IADGs. Im-
munohistochemical study showed an abnormal accumulation of pCREB in GVD granules in hippocampal neurons of AD brains. These observations suggest that aberrant CREB-mediated gene regulation serves as a molecular biomarker of AD-related pathological processes, and support the hypothesis that sequestration of pCREB in GVD granules in hippocampal neurons of AD brains. These observations suggest that deregulation of CREB-mediated gene expression in AD hippocampus.

5. Supplemental Material

Supplemental figures and tables can be found on http://www.my-pharm.ac.jp/satoj/sub19.html as downloadable PDF files.

Acknowledgements

Human brain tissues were provided by Research Resource Network (RRN), Japan. This work was supported by a research grant to J-IS from the High-Tech Research Center Project, the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan (S0801043), and from Research on Intractable Diseases, the Ministry of Health, Labour and Welfare of Japan.

References

[1] A. Serretti, P. Olgiati and D. De Ronchi, Genetics of Alzheimer’s disease: A rapidly evolving field, J Alzheimers Dis 12 (2007), 73–92.
[2] S.F. Kingsmore, I.E. Lindquist, J. Mudge, D.D. Gessler and W.D. Beavis, Genome-wide association studies: progress and potential for drug discovery and development, Nat Rev Drug Discov 7 (2008), 221–230.
[3] S.D. Ginsberg, S.E. Hemby, VM. Lee, J.H. Eberwine and J.Q. Trojanowski, Expression profile of transcripts in Alzheimer’s disease tangle-bearing CA1 neurons, Ann Neurol 48 (2000), 77–87.
[4] V. Colangelo, J. Schurr, M.J. Ball, R.P. Pelaez, N.G. Bazan and W.J. Lukiw, Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling, J Neurosci Res 70 (2002), 462–473.
[5] P. Katsel, C. Li and V. Haroutunian, Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease? Neurochem Res 32 (2007), 845–856.
[6] C. Williams, R. Mehrian Shai, Y. Wu, Y.H. Hsu, T. Sitzer, B. Spann, C. McCleary, Y. Mo and C.A. Miller, Transcriptome analysis of synaptoneurosomes identifies neuroplasticity genes overexpressed in incipient Alzheimer’s disease, PLoS ONE 4 (2009), e4936.
element-binding protein by the ubiquitin-proteasome pathway contributes to glucotoxicity in beta-cells and human pancreatic islets, *Diabetes* **58** (2009) 1105–1115.

[37] K. Okamoto, S. Hirai, T. Izuka, T. Yanagisawa and M. Watanabe, Reexamination of granulovacuolar degeneration, *Acta Neuropathol* **82** (1991), 340–345.

[38] C. Stadelmann, T.L. Deckwerth, A. Srinivasan, C. Bancher, W. Brück, K. Jellinger and H. Lassmann, Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer’s disease. Evidence for apoptotic cell death, *Am J Pathol* **155** (1999), 1459–1466.

[39] K. Leroy, A. Boutajangout, M. Antheliet, J.R. Woodgett, B.H. Anderton and J.P. Broom, The active form of glyoxen synthase kinase-3β is associated with granulovacuolar degeneration in Alzheimer’s disease, *Acta Neuropathol* **103** (2002), 91–99.

[40] S. Lagalwar, R.W. Berry and L.I. Binder, Relation of hippocampal phospho-SAPK/NIK granules in Alzheimer’s disease and tauopathies to granulovacuolar degeneration bodies, *Acta Neuropathol* **113** (2007), 63–73.

[41] A. Thakur, X. Wang, S.L. Siedlik, G. Perry, M.A. Smith and X. Zhu, c-Jun phosphorylation in Alzheimer disease, *J Neurosci Res* **85** (2007), 1668–1673.

[42] J.J. Hoorensmans, E.S. van Haaster, D.A. Nijholt, G. van Dijk and U.L. Bech, Reexamination of granulovacuolar degeneration in single neurons and autophagic granules of granulovacuolar degeneration in the Alzheimer type, *Brain Res Acta Neuropathol* **82** (1991), 340–345.

[43] B. Gong, O.V. Vitolo, F. Trinchese, S. Liu, M. Shelanski and O. Arancio, Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment, *J Clin Invest* **114** (2004), 1624–1634.

[44] Z. Liang, F. Liu, I. Grundke-Iqbal, K. Iqbal and C.X. Gong, Down-regulation of CAMKII-dependent protein kinase by over-activated calpain in Alzheimer disease brain, *J Neurochem* **103** (2007), 2462–2470.

[45] D.N. Arvantitis, A. Ducatenzeiler, J.N. Ou, E. Grodstein, S.D. Andrews, S.R. Tendulkar, A. Ribeiro-da-Silva, M. Szfy and A.C. Cuello. High intracellular concentrations of amyloid-β block nuclear translocation of phosphorylated CREB, *J Neurochem* **103** (2007), 216–228.

[46] O.V. Vitolo, A. Sant’Angelo, V. Costanzo, F. Battaglia, O. Arancio and M. Shelanski, Amyloid-β peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling, *Proc Natl Acad Sci USA* **99** (2002), 13217–13221.

[47] D. Puzzo, O. Vitolo, F. Trinchese, J.P. Jacob, A. Palmieri and O. Arancio, Amyloid-β peptide inhibits activation of the nitr o oxide/cGMP/PKA-responsive element-binding protein pathway during hippocampal synaptic plasticity, *J Biol Chem* **280** (2005), 6877–6890.
disease and in stressed human brain cells, *J Biol Chem* **283** (2008), 31315–31322.

[52] D. Gezen-Ak, E. Dursun, T. Ertan, H. Hanagasi, H. Gurvit, M. Emre, E. Eker, M. Ozturk, F. Engin and S. Yilmazer, Association between vitamin D receptor gene polymorphism and Alzheimer’s disease, *Tohoku J Exp Med* **212** (2007), 275–282.

[53] M.K. Sutherland, M.J. Somervile, L.K. Yoong, C. Bergeron, M.R. Haussler and D.R. McLachlan, Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels, *Brain Res Mol Brain Res* **13** (1992), 239–250.